Invention Grant
![Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents](/docs/US/2021-09-07/US11111245B2/abs.jpg.600x600.jpg)
- Patent Title: Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
-
Application No.: US16482867Application Date: 2018-02-01
-
Publication No.: US11111245B2Publication Date: 2021-09-07
- Inventor: Shudong Wang , Sarah Al Haj Diab , Yi Long
- Applicant: Aucentra Therapeutics Pty Ltd
- Applicant Address: AU Dulwich
- Assignee: Aucentra Therapeutics Pty Ltd
- Current Assignee: Aucentra Therapeutics Pty Ltd
- Current Assignee Address: AU Dulwich
- Agency: Meunier Carlin & Curfman LLC
- Priority: AU2017900290 20170201
- International Application: PCT/AU2018/000011 WO 20180201
- International Announcement: WO2018/141002 WO 20180809
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/437 ; A61K31/506 ; A61P35/00
![Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents](/abs-image/US/2021/09/07/US11111245B2/abs.jpg.150x150.jpg)
Abstract:
A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).
Public/Granted literature
Information query
